Genomic Health Licenses Biocartis' Idylla platform

Genomic Health Inc. (NASDAQ:GHDX) will develop an in vitro version of its Oncotype DX breast cancer assay using the Idylla molecular diagnostics platform from Biocartis Group N.V. (Euronext:BCART). Biocartis received $3.3 million up front and is eligible for milestones and royalties. The companies declined to disclose additional financial details.

Genomic Health received exclusive, worldwide rights to develop the Oncotype DX test using the platform, and may opt to license the platform for additional tests in oncology and urology...